Cellecta, Inc.
Nathan Bach is an experienced professional in business development and sales within the life sciences sector, currently serving as the Director of Business Development at Cellecta, Inc. since April 2024. Prior roles include Director of Business Development at The Jackson Laboratory and Director of Business Development for Cardiovascular and Metabolic Diseases at Crown Bioscience, where responsibilities encompassed managing non-human primate and rodent studies, conducting pharmacokinetics studies, and generating significant quarterly revenues. Nathan started their career as a Research and Development Scientist at Bristol Myers Squibb and has held various senior business development roles at Horizon Discovery, Gen9 (now part of Twist Bioscience), and GenScript. Nathan holds a PhD in Immunology from the Weizmann Institute of Science and an MSc in Biochemistry from Moscow State University.
This person is not in any teams
This person is not in any offices
Cellecta, Inc.
2 followers
Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.